In situ fabrication of alendronate-loaded calcium phosphate microspheres: controlled release for inhibition of osteoclastogenesis.
Bioabsorbable calcium phosphate (CaP) microspheres that can incorporate alendronate (ALD) through an in situ loading process and can control the ALD release rate have been described. ALD loading into CaP microspheres could be accomplished by emulsification (water-in-oil) and a subsequent CaP nucleation/growth process within the water droplets, which was initiated by a urea-mediated solution precipitation technique. ALD-loaded microspheres with a mean size range of 163-195 μm were obtained in a spherical shape. Inductively coupled plasma mass spectroscopy (ICP-MS), spectrophotometric analysis, and thermogravimetric analysis (TGA) showed that the amount of ALD loaded into the microspheres increased when the ALD feed content increased. Energy-dispersive X-ray spectroscopy (EDX) analysis revealed that the in situ loading process enabled the ALD loading throughout the microspheres. X-Ray diffraction (XRD) analysis demonstrated that crystalline hydroxyapatite (HAp) and amorphous CaP phases coexisted within the microspheres. In addition, the increased loading of ALD resulted in a larger proportion of the amorphous CaP phase within the microspheres. The ALD release rate could be controlled depending on the dissolution rate of microspheres, and ALD could be released over a period of 40 days. The evaluation of the biological activity showed that ALD-loaded CaP microspheres directly blocked osteoclast formation by releasing ALD to monocytic precursor cells and effectively inhibiting their differentiation into osteoclasts.
Kim
Chan Woo
CW
Department of Maxillofacial Biomedical Engineering and Institute of Oral Biology, School of Dentistry, Kyung Hee University, Seoul 130-701, South Korea.
Yun
Young-Pil
YP
Lee
Hong Jae
HJ
Hwang
Yu-Shik
YS
Kwon
Il Keun
IK
Lee
Sang Cheon
SC
D019386:Alendronate / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D001862:Bone Resorption / Q000473:pathology / Q000517:prevention & control*; D002130:Calcium Phosphates / Q000737:chemistry*; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D003692:Delayed-Action Preparations; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding; D004655:Emulsions; D008264:Macrophages / Q000187:drug effects; D051379:Mice; D008855:Microscopy, Electron, Scanning; D008863:Microspheres; D010010:Osteoclasts / Q000187:drug effects* / Q000473:pathology; D010316:Particle Size; D012995:Solubility; D013052:Spectrometry, X-Ray Emission; D013054:Spectrophotometry, Atomic; D013499:Surface Properties; D013817:Thermography; D014961:X-Ray Diffraction
D050071:Bone Density Conservation Agents; D002130:Calcium Phosphates; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004655:Emulsions; C020243:calcium phosphate; D019386:Alendronate